Becton, Dickinson Announces Early Tender Results and Upsizing of Tender Offers

Details

The company also announced an increase in the offer subcap for the 4.685% Senior Notes due 2044 and the aggregate offer cap to $2 billion. The tender offers are being made pursuant to the offer to purchase, dated February 10, 2026, as amended. As of the early tender date, February 24, 2026, holders had tendered various amounts of each series of securities, with the aggregate purchase price exceeding the offer cap for certain securities, leading to proration. The pricing for the tender offers was also announced on the same day. Holders who validly tendered their securities by the early tender date are eligible for the early tender payment and the total consideration for their securities.

Items reported

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.